Does a dose of 40 micrograms/day prostaglandin E1 reduce creatinine clearance in a patient with diabetic nephropathy of the nephrotic type?
The case history of a woman, who at the age of 25 years on the birth of her second child was found to be diabetic, is reported. Over the subsequent 30 years the patient had been treated with insulin, the dose administered being monitored at regular intervals. At the age of 52 years, the patient was diagnosed as suffering from hypertension and diabetic nephropathy of the nephrotic type. The patient's condition gradually deteriorated and at 55 years of age 40 micrograms/day prostaglandin E1 was given intravenously for 84 days. Treatment resulted in a decline in urinary protein without a reduction in creatinine clearance. Renograms confirmed an improvement in the vascular and secretory phases of both kidneys.
Okada
S
S
Third Department of Medicine, Okayama University Medical School, Japan.
Hamada
H
H
Ichiki
K
K
Tanokuchi
S
S
Ishii
K
K
Ota
Z
Z
Hiraki
Y
Y
D000527:Alprostadil / Q000008:administration & dosage / Q000627:therapeutic use*; D001798:Blood Proteins / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000378:metabolism*; D003928:Diabetic Nephropathies / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D003927:Diet, Diabetic; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D011866:Radioisotope Renography
D001798:Blood Proteins; D002784:Cholesterol; D003404:Creatinine; D000527:Alprostadil